| Project/Area Number |
24510283
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
System genome science
|
|---|
| Research Institution | Ritsumeikan University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
INABA Muneo 関西医科大学, 医学部, 非常勤講師 (70115947)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
JIANG Shiwen 立命館大学, 総合科学技術研究機構, 補助研究員 (10548746)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 機能性RNA / long non-coding RNA / natural antisense RNA / nucleic acid medicine / 非コードRNA / 制御性RNA / Natural antisense RNA / Competing endogenous RNA / lncRNA / NAT / ceRNA |
|---|
| Outline of Final Research Achievements |
We previously reported natural antisense RNA (AS) as an important modulator of human interferon-α1 (IFN-α1) mRNA levels by promoting the mRNA stability. Present study aims to validate the regulatory role of IFN-α1 AS on the mRNA levels in vivo, thereby, acting as a possible antiviral reagent. We therefore established a guinea pig model system in order to evaluate the effects of IFN-α1 AS in vivo. We employed a biodegradable nanospheres as a drug delivery system, which optimally contained the antisense oligoribonucleotide (ASORN), designed from the stabilization domain sequence of the AS. The nanospheres successfully delivered the ASORN to the human Influenza A virus-infected respiratory tract of the model animals, resulting in the reduction of the viral titers in the respiratory exudates from them. These results thus suggest that the IFN-α1 AS drives the host innate immunity against viral infection in in vivo condition and may lead to therapeutic intervention by the ASORN.
|
